BNGO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
8.2M
+22.2%
6.7M
-15.9%
8.0M
+7.9%
7.4M
+9.4%
6.7M
Cost of Revenue
3.9M
+12.3%
3.4M
-24.5%
4.6M
+13.9%
4.0M
+22.8%
3.3M
Gross Profit
4.3M
+32.7%
3.3M
-4.3%
3.4M
+0.9%
3.4M
-3.1%
3.5M
Operating Expenses
11.5M
+3.4%
11.1M
-6.6%
11.9M
+0.2%
11.9M
+5.6%
11.3M
R&D
3.0M
-4.8%
3.1M
-2.8%
3.2M
+13.5%
2.8M
-3.0%
2.9M
SG&A
8.5M
+6.7%
8.0M
-8.0%
8.7M
-3.9%
9.1M
+8.6%
8.3M
Operating Income
-7218000
+8.6%
-7897000
+7.5%
-8536000
+0.0%
-8538000
-9.5%
-7800000
EBITDA
-4922000
+11.9%
-5587000
+9.9%
-6199000
-0.6%
-6162000
-13.7%
-5420000
Net Income
-7423000
+10.6%
-8303000
-4.7%
-7933000
+6.7%
-8503000
-24.0%
-6857000
EPS (Basic)
$-0.64
+15.8%
$-0.76
+1.3%
$-0.77
+51.6%
$-1.59
+20.1%
$-1.99
EPS (Diluted)
$-0.64
+15.8%
$-0.76
+1.3%
$-0.77
+51.6%
$-1.59
+20.1%
$-1.99
Shares (Diluted)
11.5M
+5.2%
11.0M
+6.5%
10.3M
+93.1%
5.3M
+55.1%
3.4M
Bionano Genomics (BNGO) โ€” Financials